Par Pharmaceutical

Type: Company
Name: Par Pharmaceutical
First reported Oct 19 2014 - Updated Oct 19 2014 - 1 reports

FLUVOXAMINE MALEATE EXTENDED-RELEASE (Fluvoxamine Maleate) Capsule, Extended Release [Par Pharmaceutical, Inc.]

First reported Oct 15 2014 - Updated Oct 16 2014 - 2 reports

Intellipharmaceutics posts lower Q3 2014 net loss of USD1.7m

Pharmaceutical company Intellipharmaceutics International (TSX:I) disclosed on Wednesday its net loss of USD1.7m (USD0.07 per common share) for the three months ended 31 August 2014. This is compared with a higher net loss of USD2.0m (USD0.10 per common ... [Published Individual.com - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Court Report - October 2014 #2

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases .Teva Pharmaceuticals USA, Inc. et al. v. Mylan Pharmaceuticals Inc. et al.1:14-cv-00167; filed October 7, 2014 in the Northern District of West Virginia• ... [Published JD Supra - Oct 14 2014]
First reported Oct 10 2014 - Updated Oct 10 2014 - 3 reports

R-Tech Ueno: Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA® and Company Receives Additional Paragraph IV Notice

TOKYO--(EON: Enhanced Online News)--R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain affiliates of Takeda have ... [Published EON Science - Oct 10 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

US seeks information from 14 companies over generic drug price increases

Actavis, Dr. Reddy's Laboratories, Mylan, Sun Pharmaceutical and Teva are among 14 drugmakers that have been contacted by US Congress seeking "information about the escalating prices they have been charging for generic drugs." Congressman Elijah E Cummings ... [Published FirstWord Pharma - Oct 09 2014]
First reported Oct 08 2014 - Updated Oct 09 2014 - 1 reports

DrReddy's,Sun among 14 firms probed by US Cong over drug price

India's pharma majors Dr Reddy's and Sun Pharma are among 14 drug makers which are being probed by the US Congress over price escalation of generic drugs.In letters sent by Elijah E Cummings (Ranking Member of the House Committee on Oversight and Government ... [Published Business Standard India - Oct 08 2014]
First reported Oct 01 2014 - Updated Oct 01 2014 - 1 reports

$65M loan couches buy

Home » Finance & Accounting By REW Staff 1:27 pm, October 1, 2014 TweetMeridian Capital Group negotiated a $65 million loan for the purchase of an industrial property in Suffern, NY, on behalf of Raymour & Flanigan, a premier furniture and home ... [Published Real Estate Weekly - Oct 01 2014]
First reported Sep 30 2014 - Updated Sep 30 2014 - 1 reports

AMLODIPINE AND VALSARTAN Tablet [Par Pharmaceutical, Inc.]

First reported Sep 30 2014 - Updated Sep 30 2014 - 4 reports

Par begins shipping generic Exforge tabs

WOODCLIFF LAKE, N.J. — Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths. The tablets are the generic version of Exforge from Novartis and are used to treat hypertension ... [Published Drug Store News - Sep 30 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 3 reports

Raleigh's Salix reaches $100 million patent settlement

Raleigh’s Salix Pharmaceuticals reached a patent settlement with generic drug company Par Pharmaceutical in which the generic drug maker will pay $100 million.Salix inherited rights to ulcer medication Zegerid in its $2.7 billion acquisition of Santarus ... [Published Triangle Business Journal - Sep 22 2014]
First reported Sep 08 2014 - Updated Sep 09 2014 - 2 reports

Par Pharmaceutical resumes shipment of generic Precedex injection

Par Pharmaceutical Companies has resumed shipping dexmedetomidine hydrochloride (HCl) injection, EQ 100 mcg base/mL, the generic version of Hospira's Precedex Injection. Par immediately resumed shipping after a US District Court lifted a temporary restraining ... [Published PBR - News - Sep 09 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 2 reports

Par Pharmaceutical begins shipment of Fluphenazine Decanoate injection, USP

Par Pharmaceutical Companies has received final approval from the US Food and Drug Administration for its Abbreviated New Drug Application for fluphenazine decanoate injection, USP 25 mg/mL. ... [Published PBR - News - Jul 10 2014]

Quotes

Infringement of U S Patent Nos. 8,465,765 ( "Orally Effective Methylphenidate Extended Release Powder and Aqueous Suspension Product" issued June 18, 2013), 8,653,033 (same title, issued October 22, 2013), and 8,778,390 (same title, issued July 15, 2014) following a Paragraph IV ce...
Intellipharmaceutics CEO Dr. Isa Odidi commented, "Subsequent to our generic Focalin XR® approval, we have expanded operations and increased R&D activities, specifically around our Rexista™ oxycodone and other NDA 505(b)(2) product candidates. Such increased R&D in relation to these product candidates may require additional cash outlays. In recognition of the anticipated R&D expenditures and of the Company's current cash position, as well as our continuing commitment to the Company, Dr. Amina Odidi and I agreed to extend the maturity date of the convertible debenture relating to our loan of $1.5 million to the Company from January 1, 2015 to July 1, 2015. We believe that further growth in revenues could be realized after the exclusivity periods for the 5, 10 and 20mg doses of generic Focalin XR® expire and additional ANDA approvals are granted, but there can be no assurance as to if or when any such approvals, or expiry of any exclusivity period, will occur."
"We will continue to vigorously enforce AMITIZA's intellectual property rights," said Greenleaf. "Generic companies have made Paragraph IV certifications a routine part of business. Sucampo is well prepared to pursue all legal pathways in defense of AMITIZA."
..." Congressman Elijah E Cummings remarked "when you see how much the prices of these drugs have increased just over the past year, it's staggering, and we want to know why." Other companies contacted by Cummings and Senator Bernard Sanders include Apotex, Endo International, Global Pharmaceuticals, Heritage Pharmaceuticals...

More Content

All (61) | News (28) | Reports (0) | Blogs (31) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Rochester Regional Chamber announces annual awa... [Published Oakland Press - Oct 24 2014]
Court Report - October 2014 #3 [Published JD Supra - Oct 20 2014]
FLUVOXAMINE MALEATE EXTENDED-RELEASE (Fluvoxami... [Published DailyMed Drug Label Updates for the last seven ... - Oct 19 2014]
OTC DAILY ALERT STOCK WATCH - INTELLIPHARMACEUT... [Published 4 Traders - Oct 19 2014]
Intellipharmaceutics posts lower Q3 2014 net lo... [Published Individual.com - Oct 16 2014]
Intellipharmaceutics Announces Third Quarter 20... [Published Virtual Strategy Magazine - Oct 15 2014]
Intellipharmaceutics Announces Third Quarter 20... [Published Scottrade - Oct 15 2014]
Court Report - October 2014 #2 [Published JD Supra - Oct 14 2014]
Alpha Pro Tech (APT) Upward Path on Ebola Fears [Published Live-PR.com - Oct 10 2014]
R-Tech Ueno Announces Settlement Deal That Reso... [Published RTTNews.com - Oct 10 2014]
R-Tech Ueno: Settlement Agreement That Resolves... [Published EON Science - Oct 10 2014]
R-Tech Ueno: Settlement Agreement That Resolves... [Published Business Wire Science: Science News - Oct 10 2014]
R-Tech Ueno: Settlement Agreement That Resolves... [Published Business Wire Health News - Oct 10 2014]
Sucampo Announces Settlement Agreement That Res... [Published GlobeNewswire: Advertising News - Oct 09 2014]
Sucampo Announces Settlement Agreement That Res... [Published Pettinga Financial Advisors - Oct 09 2014]
Sucampo Announces Settlement Agreement That Res... [Published Crawford Financial Planning - Oct 09 2014]
US seeks information from 14 companies over gen... [Published FirstWord Pharma - Oct 09 2014]
DrReddy's, Sun Pharma among 14 firms probed by ... [Published zeenews.com - Oct 08 2014]
DrReddy's,Sun among 14 firms probed by US Cong ... [Published Business Standard India - Oct 08 2014]
$65M loan couches buy [Published Real Estate Weekly - Oct 01 2014]
AMLODIPINE AND VALSARTAN Tablet [Par Pharmaceut... [Published DailyMed Drug Label Updates for the last seven ... - Sep 30 2014]
Par begins shipping generic Exforge tabs [Published Drug Store News - Sep 30 2014]
DNA Diagnostics Center launches new Paternity T... [Published News-Medical.Net - Sep 30 2014]
Par Pharmaceutical Begins Shipment of Generic E... [Published Pettinga Financial Advisors - Sep 30 2014]
Par Pharmaceutical Begins Shipment of Generic E... [Published Scottrade - Sep 30 2014]
Par Pharmaceutical Begins Shipment of Generic E... [Published PR Newswire: General Business - Sep 30 2014]
Court Report - September 2014 #6 [Published JD Supra - Sep 29 2014]
Meridian Capital Group Arranges $65 Million in ... [Published City Feet - Sep 25 2014]
Par Pharmaceutical, Inc. To Pay $100 Million To... [Published BioSpace - Sep 23 2014]
Raleigh's Salix reaches $100 million patent set... [Published Triangle Business Journal - Sep 22 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FLUVOXAMINE MALEATE EXTENDED-RELEASE (Fluvoxami... [Published DailyMed Drug Label Updates for the last seven ... - Oct 19 2014]
Updated Date: Oct 14, 2014 EST ...
R-Tech Ueno: Settlement Agreement That Resolves... [Published EON Science - Oct 10 2014]
TOKYO--(EON: Enhanced Online News)--R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain affiliates of Takeda have ...
R-Tech Ueno: Settlement Agreement That Resolves... [Published Business Wire Science: Science News - Oct 10 2014]
TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain affiliates of Takeda have entered ...
R-Tech Ueno: Settlement Agreement That Resolves... [Published Business Wire Health News - Oct 10 2014]
TOKYO--(BUSINESS WIRE)--R-Tech Ueno (JASDAQ:4573): Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, its affiliate Sucampo AG, R-Tech Ueno, Ltd., Takeda Pharmaceutical Company Limited (Takeda), and certain affiliates of Takeda have entered ...
AMLODIPINE AND VALSARTAN Tablet [Par Pharmaceut... [Published DailyMed Drug Label Updates for the last seven ... - Sep 30 2014]
Updated Date: Sep 30, 2014 EST ...
1 2 3 4 5 6 7

Press Releases

sort by: Date | Relevance
Sucampo Announces Settlement Agreement That Res... [Published GlobeNewswire: Advertising News - Oct 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.